Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan Africa (COVERAGE-Africa)
Latest Information Update: 06 Feb 2023
At a glance
- Drugs Budesonide (Primary) ; Ciclesonide (Primary) ; Fluoxetine (Primary) ; Nitazoxanide (Primary) ; Telmisartan (Primary) ; Paracetamol
- Indications SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms ANTICOV; COVERAGE-A
- 30 Jan 2023 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 30 Jan 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.
- 05 Jul 2022 Number of treatment arms have been increased from 3 to 4.